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Abstract 
 
Orphenadrine is a drug acting on multiple targets, including muscarinic, histaminic, and 
NMDA receptors. It is used in the treatment of Parkinson’s Disease and in musculoskeletal 
disorders. It is also used as an analgesic, although its mechanism of action is still 
unknown. Physiological and pharmacological results both have demonstrated a critical role 
for voltage-gated sodium channels in many types of chronic pain syndromes. We tested 
the hypothesis that orphenadrine may block voltage-gated sodium channels. By using 
patch-clamp, we evaluated the effects of the drug on whole-cell sodium currents in 
HEK293 cells expressing the skeletal muscle (Nav1.4), cardiac (Nav1.5) and neuronal 
(Nav1.1 and Nav1.7) subtypes of human sodium channels, as well as on whole-cell 
tetrodotoxin (TTX)-resistant sodium currents likely conducted by Nav1.8 and Nav1.9 
channel subtypes in primary culture of rat DRG sensory neurons. The results indicate that 
orphenadrine inhibits sodium channels in a concentration, voltage and frequency 
dependent manner. Using site-directed mutagenesis, we further show that orphenadrine 
binds to the same receptor as the local anesthetics. Orphenadrine affinities for resting and 
inactivated sodium channels were higher compared to those of known sodium channels 
blockers, such as mexiletine and flecainide. Low, clinically-relevant orphenadrine 
concentration produces significant block of Nav1.7, Nav1.8, and Nav1.9 channels, which 
are critical for experiencing pain sensations, indicating a role for sodium channel blockade 
in the clinical efficacy of orphenadrine as analgesic compound. On an other hand, block of 
Nav1.1 and Nav1.5 may contribute to the proconvulsive and proarrhythmic adverse 
reactions, especially observed during overdose. 
 
 
1. Introduction 
 
Orphenadrine is an anticholinergic agent used mainly in the treatment of Parkinson’s 
disease to alleviate some of the troublesome symptoms of the disease, especially the 
involuntary resting tremor [44,45]. In addition to this use, the drug has a long history in the 
clinics as a muscle relaxant [19]. The mechanism of action for such effect remains unclear, 
but may be related in part to sedative effects; orphenadrine exerts unspecific antagonist 
activity at the phencyclidine binding site of N-methyl-D-aspartate (NMDA) receptors, one of 
the subtypes of glutamate receptors [24]. A study reported that orphenadrine is able to 
protect cultured cerebellar neurons from excitotoxicity following direct exposure of neurons 
[17]. 
Orphenadrine is used also as an analgesic both alone or in association with non 
steroidal anti-inflammatory drugs [21]. In a human model of capsaicin-dependent 
inflammatory pain obtained with laser somatosensory evoked potentials, orphenadrine 
citrate was able to exert an analgesic/anti-hyperalgesic effect in a low-dose (30 mg/day), 
which was predominantly due to central/spinal mechanisms [42]. A central action of 
orphenadrine was thus proposed, but the detailed mechanisms are unknown.  
Orphenadrine is a monomethylated derivative of diphenydramine, an antihistaminic 
drug. Since histamine plays an important role in pain processes, it is possible that the 
analgesic action of orphenadrine may be related to histamine antagonism. However, 
diphenydramine was also shown to block voltage-gated sodium channels [22], suggesting 
that other pharmacologic properties may contribute to antinociceptive effects of 
orphenadrine. Physiological and pharmacological evidence both have demonstrated a 
critical role for voltage-gated sodium channels in many types of chronic pain syndromes, 
because these channels play a fundamental role in the excitability of neurons in the central 
and peripheral nervous systems [10]. Recent findings strengthen this view, since a gain of 
function of the Nav1.7 channel, expressed at high levels in nociceptive dorsal root 
ganglion (DRG) neurons, was shown to cause primary erythermalgia and paroxysmal 
extreme pain disorder, two inherited pain syndromes linked to SCN9A mutations and 
responsive to lidocaine, mexiletine and carbamazepine treatment [15, 30, 49]. Conversely, 
loss of function of Nav1.7 channels results in an inherited channelopathy characterized by 
total insensitivity to pain of any type [9]. Moreover, expression levels of the Nav1.3 channel 
isoform increase in DRG following neuronal injury or an inflammatory insult [3]. Finally, 
knocking-out the Nav1.8 or Nav1.9 channel isoforms in mice has been shown to cause 
deficits in thermal and mechanical pain perception [1, 7, 35]. 
In the current study, we tested the hypothesis that orphenadrine may block voltage-
gated sodium channels. We evaluated the effects of the drug on muscle, cardiac and 
neuronal human subtypes of sodium channels heterologously expressed in HEK293 cells 
and elucidated the molecular mechanism of block by orphenadrine by using specific 
voltage-clamp protocols and sodium channel site-directed mutagenesis. We also tested 
orphenadrine on tetrodotoxin (TTX)-resistant sodium currents in sensory neurons 
dissociated from rat dorsal root ganglions (DRG). A major result of this study indicate that 
inhibition of voltage-gated TTX sensitive or resistant sodium channels in DRG neurons 
likely contributes to analgesic/anti-hyperalgesia effects of orphenadrine. 
 
2. Methods 
 
2.1 Mutagenesis and expression of recombinant sodium channels 
 
Full-length cDNA encoding wild-type (WT) hNav1.4 (skeletal muscle isoform), 
hNav1.5 (cardiac isoform), and hNav1.1 (central and peripheral neuron isoform) channels 
were subcloned in the mammalian expression vector pRc-CMV or pCMV-Script [5,31,48] 
and hNav1.7 (peripheral neuron isoform) was subcloned in a modified pcDNA3/pBR222 
expression vector [23].  
The F1586C mutation of hNav1.4 was engineered by standard two-step PCR-based 
site-directed mutagenesis. All PCR reactions were performed using Pfu DNA polymerase 
(Stratagene, La Jolla, CA) for high-fidelity amplification. The complete coding region of 
channel mutant cDNA was sequenced to exclude any polymerase errors. 
Transient expression of WT hNav1.5 and hNav1.7 in HEK293 cells was achieved by 
10-µg plasmid transfection using the calcium phosphate coprecipitation method [12]. 
These channels were co-transfected with the gene reporter CD8 in a 10:1 plasmid mass 
ratio. Cells identified with microbeads coated with anti-CD8 antibody (Dynal, Norway) were 
used for patch-clamp experiments 36-96 hours after transfection. Permanent expression of 
WT hNav1.1, WT hNav1.4 as well as F1586C mutant was achieved in HEK293 cells by 
the same transfection method followed by clone selection with geneticin (GIBCO-
Invitrogen, Italy). 
 
2.2 primary cultures of sensory neurons 
 
Dissociation of DRG neurons from 5-6 week-old, male Wistar rats was performed as 
previously described [7]. Briefly, the rats were deeply anesthetized with halothane and 
sacrificed by cutting the carotid arteries in accordance with the Guide for the Care and Use 
of Laboratory Animals and institutional guidelines. Excised thoraco-lumbar DRG were 
incubated for 45 min. in Hank's balanced salt solution (HBSS) supplemented with 2 mg/ml 
of collagenase Type IA (Sigma) at 37°C. After incubation, the DRG were rinsed several 
time with HBSS and gently triturated through the smoothed tip of Pasteur pipettes. 
Neurons were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% heat-inactivated fetal calf serum, 50 U/ml penicillin-streptomycin, 2 mM L-
glutamine, 25 mM glucose, 25 ng/ml nerve growth factor (Invitrogen) and 2 ng/ml glial-
derived neurotrophic factor (Invitrogen). Neurons were incubated in a humidified 
atmosphere (5 % CO2, 37°C) for 14-20 hours before recording. 
 
2.2 Voltage-clamp studies 
 
Whole-cell sodium currents (INa) were recorded at room temperature (20-22°C) using  
Axopatch 1D or 200B amplifiers (Axon Instruments, Union City, CA, USA). Voltage clamp 
protocols and data acquisition were performed with pCLAMP software (version 6.0, 9.2, or 
10.0, Axon Instruments) through a 12-bit A-D/D-A interface (Digidata 1200 or 1344, Axon 
Instruments). Patch pipettes had resistance ranging from 1 to 3 MΩ. Currents were low-
pass filtered at 2 kHz (-3 dB) by the four pole Bessel filter of the amplifier and digitized at 
10-20 kHz.  
For recordings in HEK293 cells, after rupturing the patch membrane, a 25 ms-long 
test pulse to -30 mV from a holding potential (HP) of -120 mV was applied to the cell at a 
low frequency until stabilization of INa amplitude and kinetics was achieved (typically 5 
minutes) [12]. Data were considered for analysis only from cells exhibiting series 
resistance errors <5 mV. Little (<5%) or no rundown was observed within the experiments. 
Specific voltage protocols and analysis procedures are described in the Results section. 
In DRG neurons, TTX-resistant sodium currents were recorded using specific 
voltages allowing separation of high voltage-activated (HVA) currents (known as SNS or 
PN3) and low voltage-activated (LVA) currents (known as NaN or SNS2). With TTX and 
La3+ in the bath solution, the HVA current is mainly supported by Nav1.8 sodium channels, 
whereas the LVA current results mainly from activation of Nav1.9 sodium channels 
[7,8,33]. The HVA current was elicited from a holding potential of –55 mV to a test pulse of 
–10 mV. At this HP, the Nav1.9 channels are mostly inactivated. At 0.1 and 2 Hz 
stimulation frequencies, the leak and capacitive currents were subtracted online using the 
P/4 protocol of pClamp software. At 10 Hz stimulation frequency, subtraction was 
performed offline using an adequately scaled current response to hyperpolarizing 
stimulation. The LVA current was elicited from an HP of –100 mV to –60 mV at 0.1 Hz 
stimulation frequency. At – 60 mV, the Nav1.8 channels are closed, allowing activation of 
solely Nav1.9 channels. The use of fluoride in the pipette solution increases amplitude and 
negatively shifts the voltage dependence of LVA currents. A P/6 protocol was used for leak 
and capacitive current subtraction. 
 
2.3 Drugs and solutions 
 
All reagents as well as hydrochloride salts of mexiletine and orphenadrine were 
purchased from Sigma-Aldrich (Milan, Italy), except differently indicated. For patch-clamp 
recordings of heterologously expressed sodium channels, the pipette solution contained in 
mM 120 CsF, 10 CsCl, 10 NaCl, 5 EGTA and 5 Hepes, and the pH was set to 7.2 with 
CsOH, while the bath solution contained in mM 150 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 5 
Hepes and 5 glucose. The pH was set to 7.4 with NaOH. For patch-clamp recordings in 
DRG sensory neurons, the pipette solution contained in mM 100 CsCl, 30 CsF, 8 NaCl, 
2.4 CaCl2, 1 MgCl2, 5 EGTA, 10 Hepes, 4 ATP, and 0.4 GTP, and the pH was set to 7.3 
with NaOH. The bath solution contained in mM 131 NaCl, 3 KCl, 2.5 CaCl2, 1 MgCl2, 10 
Hepes, 10 glucose, 0.5 tetrodotoxin (TTX), and 5 La3+. The pH was set to 7.35 with NaOH. 
Orphenadrine was diluted in bath solution at desired concentration and the pH was 
adjusted to 7.4. The patched HEK293 cell was continuously exposed to a stream of control 
or drug-supplemented bath solution flowing out from a plastic capillary. During recordings, 
the DRG neurons were perfused with bath solution at a flow rate of 3 ml/min. The bath 
solution was recycled to limit sparing of TTX. Both perfusion systems allowed application 
of drug in less than 1 min. 
 
2.4 Statistical analysis 
 
Average data are presented as means ± S.E.M. and statistical difference between the 
means was evaluated using Student’s unpaired or paired t-test, with P < 0.05 considered 
as significant. 
 
3. Results 
 
3.1 Dose- and frequency-dependent block of four sodium channel subtypes by 
orphenadrine 
 
We tested orphenadrine on four sodium channel subtypes encoded by different 
genes. While the hNav1.4 channel (SCN4A gene) is expressed exclusively in skeletal 
muscle, the hNav1.5 channel (SCN5A gene) is the main cardiac isoform and is expressed 
also in some areas of the central nervous system as well as in immature or denervated 
skeletal muscle, the hNav1.1 channel (SCN1A gene) is expressed in central and 
peripheral neurons and cardiac myocytes, and the hNav1.7 channel (SCN9A) is 
predominantly expressed in peripheral neurons, including the DRG where it is 
concentrated in small C fiber nociceptors [4]. Wild-type hNav1.1, hNav1.4, hNav1.5, and 
hNav1.7 channels were transiently or permanently expressed in HEK293 cells, and the 
resulting INa were recorded with patch-clamp technique in the whole-cell configuration [12]. 
Externally applied orphenadrine produced both tonic and use-dependent block of INa  
elicited by depolarizing pulses to -30 mV from an holding potential (HP) -120 mV. Tonic 
block was assayed 3 min after drug application by measuring the reduction of INa elicited at 
0.1 Hz, whereas use-dependent block was further obtained by increasing stimulation 
frequency to 10 Hz. Applying this protocol in the absence of drug produced no significant 
change in INa amplitude (not shown). Figure 1A shows representative examples of hNav1.4 
current traces recorded before (control) and after application of 30 µM orphenadrine. The 
drug reduced the amplitude of peak INa by 24 ± 6 % at 0.1 Hz and 81± 5 % at 10 Hz (n=4). 
Figure 1B shows representative examples of hNav1.7 current traces recorded in the 
presence of 100 µM orphenadrine. The drug reduced the amplitude of peak INa by 48 ± 4 
% at 0.1 Hz and 82 ± 4 % at 10 Hz (n=4). The inhibitory effect of orphenadrine was dose-
dependent. The concentration-response curves were fitted with the first-order binding 
function,  
IDRUG/ICONTROL = 1/{1+([drug]/ IC50)nH}  (1)  
where IC50 (µM) is the half-maximum inhibitory concentration and nH is the slope factor 
(Fig. 1C and D). The values of IC50 and nH are reported in Table 1. Little or no difference 
was found between the four sodium channel isoforms. Compared to the effects of the well-
known sodium channel blockers, mexiletine and flecainide, on hNav1.4 in the same 
experimental conditions, orphenadrine was equipotent to flecainide and more potent than 
mexiletine at 0.1 Hz, while its IC50 at 10 Hz was about 3-fold smaller than that of the two 
other drugs indicating a high frequency-dependent profile [12,13]. The block of 
orphenadrine of sodium channel was completely reversible (see below). 
 
3.2 State-dependent binding affinities of orphenadrine to hNa1.4 channels 
 
According to the modulated receptor hypothesis, use-dependent block can be 
explained from different binding affinities to the closed and open/inactivated channels [20]. 
For similar reason, the block of INa at the HP of -120 mV probably reflects the combination 
of binding to both the resting and inactivated sodium channels at this HP [12,50]. We 
calculated the drug-binding affinities to resting (KR) and inactivated (KI) sodium channels 
using hNav1.4 to allow direct comparison with data previously obtained with mexiletine 
and flecainide. To evaluate KR, we first measured tonic block of the channels while 
maintaining the cell hyperpolarized at -180 mV for 120 s (prepulse) and, only after that, the 
cell was depolarized at 0.1 Hz frequency (Fig. 2A, B). At the HP of -180 mV, the entire 
population of the channels are in the closed state, ready to open in response to the first 
pulse depolarization. No change in INa occurred in absence of drug. In presence of drug, a 
reduction of INa amplitude, labeled tonic block (TB), was observed on the first pulse after 
the 120 s-long prepulse, which reflects binding to closed channels. Little or no additional 
block was observed at 0.1 Hz. At 10 Hz, a huge use-dependent block developed, which 
was reversed on turning back to 0.1 Hz stimulation. Finally, TB can be fully reversed by 
washing out the drug. We calculated the KR as the IC50 value of concentration-response 
curves for TB occurring during the prepulse (Fig. 2C). The calculated KR for orphenadrine 
was 161 ± 23 µM. For comparison, the KR values for mexiletine and flecainide on hNav1.4 
channels were 800 µM and 480 µM, respectively [12,13]. Thus orphenadrine binds to 
resting sodium channels with relatively high affinity. 
Because inactivated channels are non-conducting, calculation of affinity constant for 
inactivated channels can be only indirect. We calculated the TB at HP= -90 mV using the 
same protocol as in Fig. 2A, except a 35 ms-long hyperpolarized pulse at -180 mV was 
introduced before the test-pulse at -30 mV to allow inactivated at -90 mV channel to 
recover from inactivation, thereby assuring that the reduction of INa was attributable only to 
closure of drug-bound channels (Fig. 3A). In these conditions, the IC50 value for TB was 
23.6 ± 3.4 µM (KAPP in equation 2). Using the Bean’s equation derived from the modulated 
receptor hypothesis,  
KI = (1-h)·(1/KAPP - h/KR)-1  (2) 
where KAPP is the apparent affinity constant at the potential considered and the terms h 
and (1-h) are the proportions of closed and inactivated channels at this potential as 
determined from steady-state inactivation curves (Fig. 3B) [2]. With h = 0.9197 at -90 mV, 
the calculated KI value was 2.2 µM. Compared to mexiletine (KI = 6 µM) and flecainide (KI 
= 18 µM) on hNav1.4 channels, orphenadrine appeared as a potent blocker of sodium 
channels inactivated from the closed state [13]. 
 
3.3 Orphenadrine binds to the local anesthetic receptor 
 
Sodium channel block characteristics suggest that orphenadrine may bind to the local 
anesthetic receptor within the channel pore. In particular, the aromatic moiety and the 
charged amine of LAs were proposed to interact with two aromatic residues of the 
segment 6 of domain IV (Phe1764 and Tyr1771 in the rat Nav1.2 channel) through 
hydrophobic and π-cation interactions [39]. The phenylalanine residue appeared as the 
more important amino acid for inactivated channel block. This amino acid is conserved in 
the various mammalian voltage dependent sodium channel subtypes (Fig. 4A). We 
engineered the corresponding F1586C mutation into the hNav1.4 template. The mutant 
express well in HEK cells and clones with permanent expression were obtained. Similarly 
to F1764A in Nav1.2, the F1586C mutation in hNav1.4 positively shifted the voltage-
dependence of channel availability by 7.9 mV (Table 1). The local anesthetic mexiletine 
was first tested on the F1586C mutant to verify whether this amino acid is critical for LA 
binding in hNav1.4 channels (Fig 4B and D). The IC50 values for block of F1586C channels 
by mexiletine were 1340 μM at 0.1 Hz and 1089 μM at 10 Hz, compared  to IC50 values of 
235 μM at 0.1 Hz and 37 μM at 10 Hz for blocking wild-type (WT) hNav1.4 channels in 
similar conditions [12]. Thus mexiletine was 6-fold (0.1 Hz) and 29-fold (10 Hz) less potent 
in blocking F1586C mutants than WT channels. Consequently the IC50 value for F1586C 
blockade at 0.1 Hz was greater than the KR of mexiletine for WT channels (~800 μM, see 
ref. [12]), and the use-dependence was almost zeroed by the mutation, confirming that the 
phenylalanine residue in position 1586 is critical for binding of LAs to inactivated channels. 
Importantly, the effects of orphenadrine on F1586C recapitulated those of mexiletine (Fig. 
4C and E). At 0.1 Hz, 100 µM orphenadrine was needed on F1586C currents to obtain an 
effect similar to 30 µM on WT channels. The concentration-effect relationships of 
orphenadrine on F1586C sodium currents indicated a IC50 value of 206 ± 10 µM at 0.1 Hz 
and 127 ± 14 µM at 10 Hz, which are about two- and ten-fold greater than those measured 
for WT channels. As for mexiletine, the IC50 value for F1586C blockade was greater than 
the KR for WT channels, and very little use-dependent block was observed on F1586C 
currents. 
 
3.4 Use-dependent block of hNav1.7 channels by clinical dose of orphenadrine 
 
The serum concentrations of orphenadrine used clinically for analgesia are in the 
range of 0.1-0.4 µg/mL, corresponding to 0.03-0.13 µM [26]. Thus we tested the effects of 
0.1 μM orphenadrine on hNav1.7 channels using various stimulation frequency and a 
holding potential of -90 mV (Fig. 5). At this HP, significant use-dependent reduction of 
sodium currents was observed in absence of drug at 5 and 10 Hz frequencies. However, 
the reduction of sodium currents was significantly accentuated in presence of the low drug 
concentration. Steady-state reduction of peak sodium current was significantly greater with 
the drug compared to control condition at all the three stimulation frequency tested (Fig. 
5D). 
 
3.5 Effects of orphenadrine on TTX-resistant sodium currents in DRG neurons 
 
Other than the tetrodotoxin-sensitive Nav1.7 channel isoform, the tetrodotoxin-
resistant Nav1.8 and Nav1.9 subtypes are expressed in DRG neurons and are involved in 
pain sensation [1,27,33,35,40]. Both these channels have proved very difficult to express 
in heterologous systems, thus we studied the effects of orphenadrine on TTX-resistant 
sodium currents in primary cultures of DRG neurons [36]. In sensory neurons, the Nav1.8 
channels conduct an HVA sodium current that is the main responsible for action potential 
rising phase. In contrast the Nav1.9 channel is the molecular correlate of a persistent, LVA 
sodium current that is potentiated by inflammatory mediators, thereby increasing sensory 
neuron excitability during peripheral inflammation. Because of their peculiar voltage 
dependence, the two channels can be distinguished by using specific protocols. 
For recording of Nav1.8 currents, we used a depolarized holding potential (-55 mV) 
that pushes Nav1.9 channel into a slow inactivated state. A depolarized HP also allows to 
record HVA currents of limited amplitude (1-5 nA) to improve voltage clamp. 
Representative examples of HVA currents are shown in figure 6. Please note that, as 
expected for Nav1.8 channels, HVA current activation and inactivation were slower with 
respect to sodium currents recorded in HEK cells. At 0.1 Hz stimulation, 0.1 µM 
orphenadrine had a small effect on current amplitude, whereas 1, 10 and 30 µM 
orphenadrine produced significant reduction (Fig. 6A). The IC50 value for inhibition of 
Nav1.8 channels in these conditions was 6.3 µM (Fig. 6B). We also studied the use-
dependent inhibition of Nav1.8 currents by orphenadrine (Fig. 7). In absence of drug, 
current amplitude is stable at 0.1 Hz stimulation, but is greatly reduced by increasing the 
stimulation frequency to 2 and 10 Hz. As previously observed in figure 6, using 0.1 Hz 
stimulation, orphenadrine produced little tonic block at 0.1 µM but huge current inhibition at 
10 µM. In addition, use-dependent reduction of sodium currents at  2 and 10 Hz was 
significantly greater in presence of 0.1 and 10 µM of orphenadrine. 
To record LVA currents, we used an holding potential of -100 mV and a test pulse at -
60 mV. In the presence of TTX to block TTX-sensitive sodium channels and La3+ to block 
T-type calcium channels, the LVA currents are mainly supported by Nav1.9 channels [7]. 
The Nav1.9 channels are rather atypical with respect to other sodium channel subtypes, 
generating little-inactivating, persistent sodium currents at hyperpolarized potentials (Fig. 
8). Using fluoride as the main intracellular anion, amplitude of the LVA current increased 
dramatically within 3-5 minutes after patch membrane rupture [8,34]. However, current 
amplitude ran down soon after, reaching a more stable low amplitude level, as shown in 
Figure 8A. When applied on the maximally-activated Nav1.9 current, orphenadrine (10 µM) 
reduced current amplitude by 29.4 % (Fig. 8B). The drug effect was partly reversed upon 
washout, while currents were entering the run-down process. When applied on the 
residual current after run-down, orphenadrine reversibly decreased Nav1.9 currents by 
28.7 % (Fig. 8C). In average, the inhibition of Nav1.9 currents by 10 µM orphenadrine was 
28.5 ± 0.9 % (n= 5). 
 
4. Discussion 
 
Orphenadrine is a drug acting on multiple targets, including histaminic, muscarinic,  
and NMDA receptors, as well as the noradrenaline reuptake system, although it shows 
lower affinity with respect to known specific ligands [24,37,41,46]. It was introduced into 
the market as a medication for Parkinson’s disease, providing control of symptoms when 
used as monotherapy, but its psychotoxic, cognitive and autonomic adverse events may 
limit its use in some patients [29]. Randomized trials have also demonstrated muscle 
relaxing properties of orphenadrine without impairment of normal muscle tone or voluntary 
movements [6]. Orphenadrine is also used as analgesic either alone or in combination with 
paracetamol/acetaminophen [21]. The antinociceptive effect of orphenadrine was 
investigated in mice, suggesting that the drug may reduce different types of nociceptive 
transmission. In humans, orphenadrine proved benefits with respect to placebo against 
shoulder, neck, and low back pain, as well as acute and chronic painful musculoskeletal 
conditions [21]. More recently, orphenadrine was able to exert an analgesic/anti-
hyperalgesic effect in a human model of capsaicin-dependent inflammatory pain [42]. The 
exact molecular mechanism by which orphenadrine induces analgesia is still unknown. It is 
possible that antihistaminergic properties and NMDA-receptor inhibition may play a role for 
the observed analgesic effects. Our results strongly support the inhibition of voltage-gated 
sodium channels as a contributor to analgesic action of orphenadrine. 
We demonstrate that orphenadrine blocks voltage-gated sodium channels with a 
mechanism analogous to a local anesthetic: effect is concentration, voltage, and 
frequency-dependent. Moreover, the F1586C mutation, located at a position putatively 
involved in LA binding, greatly reduces INa inhibition by orphenadrine and zeroes use-
dependence, as it does for mexiletine. This result indicates that the phenylalanine is 
important for the binding of orphenadrine to inactivated sodium channels. The molecule of 
orphenadrine has a chemical structure similar to sodium channel blockers, like the local 
anesthetic lidocaine, the antiarhythmic mexiletine, and the anticonvulsant phenytoin, which 
consists of an aromatic hydrophobic tail linked to a hydrophilic tertiary amine group by 
ester chain. Its pKa (9.05 ± 0.01) and Log P (3.78 ± 0.01) values indicate that neutral form 
is highly lipophilic, while the charged form predominates at physiological pH (percentage of 
ionization is 97.8 % at pH 7.4, as calculated with Handerson-Hasselbach equation). 
Voltage- and use-dependent block are related to different affinities for closed and 
inactivated channels. The KR for orphenadrine is about 5-fold and 3-fold lower compared 
to those of mexiletine and flecainide, while the KI is 3-fold and 9-fold reduced, respectively 
[12,13]. These results indicate that orphenadrine is a potent blocker of closed and 
inactivated sodium channels. On one hand, the superior lipophilia of orphenadrine may 
favor access of the drug to closed channels; on the other hand, the diphenyl structure 
would strengthen drug-channel interactions at the binding site, especially to the inactivated 
channel. Indeed, It has been found that other diphenyl compounds have a binding affinity 
to the inactivated sodium channels ~100-fold higher than to the resting channels [25]. 
The use-dependence block of sodium channels may contribute to the clinical efficacy 
of orphenadrine as analgesic compound. Indeed, it has been hypothesized for many years 
that voltage-gated sodium channels might play specialized roles in nociception and pain 
mechanisms [10]. It is clear from animal studied that Nav1.7, Nav1.8 and Nav1.9 all play 
important roles in inflammatory and neuropathic pain. Voltage-gated sodium channels in 
sensory neurons have been implicated in several chronic painful neuropathies that arise 
from peripheral nerve injury [27,40]. Human studies have shown that Nav1.7 is crucial for 
experiencing physiological pain sensations since gain-of-function mutations in the SCN9A 
gene encoding this channel subtype can result in severe chronic pain sensations [15]. 
Many types of pain appear to reflect neuronal hyperexcitability, so the use-dependent 
block of sodium channel is thought to be effective in the treatment of chronic pain [14]. We 
observed a significant use-dependent block of hNav1.7 channels at the hp of -90 mV with 
the clinically-relevant 0.1 μM concentration of orphenadrine, suggesting that clinical doses 
may produce a very significant block of high-frequency action potential firing in 
depolarized, physiologic or pathologic conditions. We also demonstrated that low doses of 
orphenadrine blocks tetrodotoxin-resistant sodium channels in DRG sensory neurons, 
which are conducted by Nav1.8 and Nav1.9 channel subtypes. Because orphenadrine 
blocks both tetrodotoxin-sensitive (Nav1.1, Nav1.4, Nav1.7) and tetrodotoxin-resistant 
(Nav1.5; Nav1.8, Nav1.9) channel subtypes, it is quite probable that the block of the entire 
cohort of sodium channels expressed in sensory neurons may contribute to its analgesic 
action. 
On the other hand, blood concentrations of orphenadrine greater than 0.5 µg/mL 
(~0.2 µM) may cause toxic reactions [28]. Such toxic effects are frequently observed 
because orphenadrine is widely available and the drug can be deliberately abused for its 
analgesic, stimulating, and euphoriant effects, as well as for suicide purpose [18,38]. 
Besides anticholinergic side effects, orphenadrine can produce both central and peripheral 
adverse reactions, including generalized tonic-clonic seizures and life-threatening 
arrhythmias [11,16]. Low dose of orphenadrine was also shown to precipitate long QT and 
Torsades-de-Pointes tachycardia in a patient with congenital long QT syndrome [32]. 
Recent studies suggest that cardiac and neuronal toxicity may be linked to the action of 
orphenadrine on HERG channels, which contribute to the action potential repolarization 
phase in the heart and to spike-frequency accommodation in the nervous system [43,47]. 
Our results show that orphenadrine inhibits the sodium channel subtypes expressed in 
heart and central neurons. Although sodium channel blockers may be used as 
antiarrhythmics and anticonvulsants for their use-dependent mechanism of action, 
exaggerated inhibition of sodium currents by high orphenadrine doses would induce 
proarrhythmic and proconvulsive effects, especially because the drug displays a relatively 
high affinity to resting channels. 
In conclusion, our study shows that orphenadrine blocks different subtypes of 
voltage-gated sodium channels at clinically relevant doses, including the Nav1.7, Nav1.8 
and Nav1.9 channel subtypes that are primarily involved in nociception. These results 
indicate a new mechanism likely contributing to its analgesic effect. On the other hand, the 
inhibition of sodium channels in various tissues may be a source for toxic reactions. 
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Table 1. IC50 values for orphenadrine block of four human voltage-gated sodium channel 
isoforms and the F1586C hNav1.4 mutant. 
 IC50 at 0.1 Hz 
(µM) 
nH at 0.1 Hz IC50 at 10 Hz 
(µM) 
nH at 10 Hz V1/2 (mV) 
hNav1.4 92.9 ± 12.0 1.3 ± 0.2 13.2 ± 1.1 1.5 ± 0.2 -72.3 ± 0.2 (17) 
hNav1.5 70.4 ± 6.1 1.2 ± 0.1 13.0 ± 1.2  1.3 ± 0.2 -79.7 ± 0.7 (17) 
hNav1.1 110.3 ± 10.2 1.3 ± 0.1 12.9 ± 2.1 1.2 ± 0.2 -71.0 ± 0.2 (18) 
hNav1.7 92.1 ± 9.1 1.2 ± 0.1 17.2 ± 1.9 1.1 ± 0.1 -62.1 ± 0.7 (20) 
F1586C 206 ± 10 1.4 ± 0.1 127 ± 14 1.2 ± 0.2 -64.4 ± 0.2 (24) 
The half-maximum inhibitory concentration (IC50) and the slope factor (nH) values were 
calculated using equation (1) at the HP of -120 mV from the concentration/response 
relationships shown in Fig. 1 and 4. The half-maximum inactivation potential (V1/2) was 
calculated from the fit with Boltzmann equation of steady-state inactivation relationships 
obtained as in Fig. 3B using the cells (number indicated within brackets) used for 
determination of IC50 value. 
  
 
Fig. 1. Dose-dependent and use-dependent block of four sodium channel subtypes by 
orphenadrine. The block of sodium currents by orphenadrine was assessed 3 min after 
drug application by measuring the reduction of INa elicited with a 25 ms-long test pulse 
from −120 mV to −30 mV at stimulation frequencies of 0.1 and 10 Hz. A, Effects of 30 µM 
orphenadrine on hNav1.4 currents B, Effects of 100 μM orphenadrine on hNav1.7 
currents. The concentration-response curves for orphenadrine block were constructed at 
0.1 (C) and 10 Hz (D) and fitted with equation (1). Each data point is the mean ± S.E.M. of 
at least 3 cells. The calculated IC50 and nH values ± S.E. of the fit are reported in Table 1. 
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Fig. 2. Affinity of orphenadrine for 
resting, closed hNav1.4 channels. A, 
time course of peak INa in a HEK293 
cell expressing hNav1.4 channels. The 
cell was held at the HP of −180 mV 
and depolarized for 25 ms to −30 mV 
at 0.1 Hz (plain circles) and 10 Hz 
(open circles), except in 
correspondence to arrows where the 
HP was maintained with no 
depolarization. Tonic block was 
measured in presence of 100 µM 
orphenadrine at the first pulse 
depolarization. Little or no block was 
observed at 0.1 Hz, whereas a huge 
use-dependent block was observed at 
10 Hz. B, traces of hNav1.4 INa 
measured at the times reported in A: 
ICTRL was measured just before 
application of the drug, ITB correspond 
to tonic block, I0.1 corresponds to the 
steady-state block reached at 0.1 Hz, 
and I10 corresponds to the steady-
state block at 10 Hz. C, concentration-
response curve was constructed for 
tonic block (ITB/ICTRL) of hNav1.4 INa 
currents measured as in A. Each data 
point is the mean ± S.E.M. of at least 3 
cells. The relationship was fitted with 
equation (1), where the calculated IC50 
corresponds to affinity to resting, 
closed channels KR. The KR value ± 
S.E. of the fit was 161 ± 23 µM. The 
calculated slope factor nH ± S.E. of 
the fit was 1.2 ± 0.2. 
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Fig. 3. Affinity of orphenadrine for inactivated hNav1.4 channels. A, concentration-
response curve was constructed for ITB/ICTRL measured as in Figure 2A, except the HP was 
-90 mV and a 35 ms-long hyperpolarized pulse at -180 mV was introduced before the test-
pulse at -30 mV to allow inactivated at -90 mV channel to recover from inactivation, 
thereby assuring that the reduction of INa was attributable only to closure of drug-bound 
channels. Each data point is the mean ± S.E.M. of at least 3 cells. The relationship was 
fitted with equation (1), where the calculated IC50 value corresponds to apparent affinity 
constant (KAPP). The KAPP value ± S.E. of the fit was 23.6 ± 3.4 µM. The calculated slope 
factor nH ± S.E. of the fit was 1.0 ± 0.1. B, steady-state inactivation curve of INa in a 
HEK293 cell expressing hNav1.4. INa was evoked by a 20 ms-long test pulse to − 30 mV 
after a 50 ms-long conditioning pulse to potentials ranging from −150 to −30 mV in 10-mV 
increments; the HP was −180 mV. The peak INa recorded during the test pulse was plotted 
against the conditioning pulse potential. The relationship was fitted with the Boltzmann 
equation, INa/INa,max = 1/{1+exp[(V − V1/2)/S]}, where V1/2 (mV) is the half-maximum 
inactivation potential and S (mV) is the slope factor. Each data point is the mean ± S.E.M. 
of the 18 cells used for determination of KAPP. The V1/2 value ± S.E. of the fit was -73.2 ± 
0.1 mV. The calculated slope factor S ± S.E. of the fit was -7.0 ± 0.1 mV. From this 
relationship, the proportions of closed (h) and inactivated (1 - h) channels was determined 
at -90 mV and inserted together with KR and KAPP values into equation (2) to calculate the 
affinity for inactivated channel (KI), which was 2.2 µM. 
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Fig. 4. Binding of orphenadrine and mexiletine to the local anesthetic receptor. A, 
Alignment of aminoacidic sequence within the 6th segment of domain IV of the α sodium 
channel subunit of rat neuronal (rNav1.2), human neuronal (hNav1.2), and human skeletal 
muscle (hNav1.4) channels. The phenylalanine residue, originally found in rNav1.2 to be 
critical for binding of local anesthetics, is conserved among sodium channel subtypes and 
among species. The corresponding F1586C mutation was introduced into the hNav1.4 
template. B and C, Representative traces of INa recorded in HEK293 cells expressing the 
F1586C hNav1.4 channel. Mexiletine and orphenadrine block was assessed 3 min after 
drug application by measuring the reduction of INa elicited with a 25 ms-long test pulse 
from −120 mV to −30 mV at stimulation frequencies of 0.1 and 10 Hz. D and E, 
concentration-response curves for mexiletine and orphenadrine block were constructed at 
0.1 and 10 Hz using the protocol described above and fitted with equation (1). Each data 
point is the mean ± S.E:M. of at least 3 cells. For mexiletine, the calculated IC50 values ± 
S.E. of the fit were 1340 ± 72 µM at 0.1 Hz and 1089 ± 181 µM at 10 Hz. The calculated 
slope factor nH ± S.E. of the fit were 1.1 ± 0.1 at 0.1 Hz and 1.0 ± 0.2 at 10 Hz. For 
orphenadrine, the calculated IC50 and nH values are reported in Table 1.  
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Fig. 5. Use-dependent block of hNav1.7 channels by the clinically-relevant 0.1 μM 
concentration of orphenadrine. A, B, and C, Sodium currents were elicited with a 12 ms-
long test pulse at -30 mV from the holding potential of -90 mV at 2, 5, or 10 Hz in control 
conditions (CTRL) then in presence of 0.1 μM orphenadrine. The peak current amplitude 
was normalized with respect to the first test-pulse peak current amplitude and plotted 
against the test-pulse number. Each point is the mean ± S.E.M. from 5 cells. D, The last 
ten amplitude values (pulse number 41 to 50 at 2 Hz and 91 to 100 at 5 and 10 Hz) were 
averaged to calculate the percentage of use-dependent inhibition at steady state. Paired 
Student’s t-test indicated significant differences (at least P<0.01) between CTRL and drug 
at the three stimulation frequencies tested. 
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Fig. 6. Tonic block of Nav1.8 channels by orphenadrine in rat DRG sensory neurons. A,  
High-voltage activated (HVA) currents were recorded in primary culture of rat DRG 
neurons with whole-cell patch-clamp technique by depolarizing the cell to -10 mV for 25 
ms from an holding potential of -55 mV every 10 s (frequency stimulation of 0.1 Hz). With 
tetrodotoxin in the bath solution, the HVA currents are supported mainly by the Nav1.8 
sodium channel subtype. Current traces were recorded in a representative neuron before 
(CTRL) and after successive application of 0.1, 1, 10, and 30 µM orphenadrine. B, 
concentration-response curve for tonic block of Nav1.8 channels by orphenadrine was 
constructed at 0.1 Hz using the protocol described in A and fitted with equation (1). Each 
data point is the mean ± S.E.M. from at least 3 DRG neurons. The calculated IC50 values ± 
S.E. of the fit were 6.3 ± 1.4 µM and the slope factor nH was 0.97 ± 0.19. 
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Fig. 7. Use-dependent block of Nav1.8 channels by orphenadrine in rat DRG sensory 
neurons. A, HVA sodium currents were recorded in a representative rat DRG neuron as in 
figure 6 using 0.1, 2, and 10 Hz stimulation frequency before and after successive 
applications of 0.1 and 10 µM orphenadrine. B, time course of use-dependent reduction of 
Nav1.8 currents in the same neuron as in A at 2 (left) and 10 (right) Hz stimulation 
frequency before and after successive applications of 0.1 and 10 µM orphenadrine. C, 
Mean ± S.E.M. percentage of use-dependent Nav1.8 current reduction measured in 4 
DRG neurons before and after successive applications of 0.1 and 10 µM orphenadrine. 
The symbol * indicates significant difference (at least P<0.05) with respect to control 
condition (no drug) calculated with paired Student’s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Effects of orphenadrine on Nav1.9 channels in rat DRG sensory neurons. A, low-
voltage activated (LVA) currents were recorded in primary culture of rat DRG neurons with 
whole-cell patch-clamp technique by depolarizing the cell to -60 mV for 100 ms from an 
holding potential of -100 mV every 10 s (frequency stimulation of 0.1 Hz). With tetrodotoxin 
and La3+ in the bath solution, the LVA currents are conducted mainly by the Nav1.9 
sodium channel subtype. A, Representative time course of the characteristic run-down of 
Nav1.9 currents recorded with intracellular fluoride in a DRG neuron. Right panel shows 
current traces extracted at time a (maximum activity) and b (after run-down). B, Time 
course of current amplitude when 10 µM orphenadrine was applied on the maximally-
activated Nav1.9 currents in a representative DRG neuron. Right panel shows current 
traces extracted at time a (maximum Nav1.9 current activation), b (during application of 
orphenadrine), c (under drug washout), and d (after run-down). C, Time course of current 
amplitude when 10 µM orphenadrine was applied on Nav1.9 currents after run-down in a 
representative DRG neuron. Right panel shows current traces extracted at time a (after 
run-down), b (during application of 10 µM orphenadrine), and c (under drug washout). 
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